RAD-AID Is Bringing AI Radiology to Hospitals That Have No Radiologists

RAD-AID International is a nonprofit that works to improve and expand radiology services in medically underserved regions, and its AI program matters because roughly two thirds of the world's population has little or no access to medical imaging. In the low and middle income countries where RAD-AID operates, hospitals may share a single X-ray machine with no trained radiologist to read the images for weeks at a time. Artificial intelligence, deployed carefully, can stand in that gap as a first reader and triage tool.

What sets RAD-AID apart from vendors simply shipping software abroad is its method. In a strategy framework published in the journal Radiology in 2020, RAD-AID researchers laid out a three pronged integrated approach for AI adoption in resource poor hospitals: clinical radiology education, infrastructure implementation, and phased AI introduction. The order matters. AI arrives last, after people and systems are ready for it.

Why Radiology Is the Bottleneck

Imaging sits at the center of modern diagnosis. Chest X-rays guide treatment for tuberculosis and pneumonia. Ultrasound monitors pregnancies. Mammography detects breast cancer early enough to treat it. But imaging without interpretation is just a picture, and interpretation requires specialists whose training takes more than a decade. Low income countries have a small fraction of the radiologists per capita that wealthy countries do, and most of those specialists work in capital cities.

The consequence is a system where scans are taken but not read, or read too late to change outcomes. RAD-AID, which operates programs across dozens of countries from Peru to Ethiopia to India, has spent over a decade attacking this problem with volunteer radiologists, technologist training, and equipment donations. AI became a natural extension of that work.

Triaging X-Rays in Peru and Beyond

One of RAD-AID's flagship training sites is in Cusco, Peru, where its programs include AI education alongside clinical ultrasound and radiology training. The idea is that local clinicians learn both how to use AI tools and how to scrutinize them, understanding what the algorithms flag, what they miss, and when a human must overrule the machine. This training first philosophy addresses the biggest failure mode of global health AI pilots, tools that arrive with fanfare and sit unused because no one on site trusts or understands them.

Through partnerships, RAD-AID has also helped bring specific AI products to hospitals that need them. With the cancer detection company iCAD, RAD-AID supported what the organizations describe as the first AI based mammography decision support program in Guyana, giving clinicians a second reader for breast cancer screening in a country with very few breast imaging specialists. And with support from Google's AI for Global Goals initiative, RAD-AID has worked with low resource hospitals to use AI to triage and interpret X-rays and communicate results, with a focus on respiratory disease and breast cancer.

The Phased Introduction Model

RAD-AID's published framework is deliberately unglamorous. Before any algorithm is switched on, the team assesses whether a hospital has reliable electricity, functioning imaging equipment, network connectivity, and staff who can act on AI findings. AI is then introduced in phases, starting with retrospective testing on local images to verify the tool performs adequately on the local population, followed by supervised clinical use and ongoing monitoring.

This rigor reflects hard lessons from the field. An algorithm trained on images from modern digital machines may falter on older equipment or different patient populations. Deploying it without validation risks eroding trust in the entire technology. RAD-AID treats AI not as a gadget but as a clinical intervention that carries the same obligations of evidence and oversight as a new drug or device.

A Template Others Are Following

The RAD-AID model, pairing AI tools with human training and infrastructure investment, has become a reference point for the wider global health community. The World Health Organization now recommends computer aided detection for tuberculosis screening, and AI reading of chest X-rays has been deployed in dozens of countries. Each of those deployments will face the same questions RAD-AID has spent years answering: who reads the scan when the algorithm is uncertain, who maintains the machine, and who is accountable for the diagnosis.

The promise of AI radiology in poor countries is not replacing doctors. It is making the few doctors who are there go further, catching the pneumonia, the tumor, the fracture that would otherwise wait months for a reader. In hospitals where a delayed X-ray read can be a death sentence, that is the kind of artificial intelligence worth celebrating.